⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25359531 | 0.97 | FDPS (0.36) | — | |
| SCHEMBL3440713 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL25412817 | 0.93 | — | — | |
| SCHEMBL23672272 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL25415142 | 0.86 | — | — | |
| SCHEMBL6398836 | 0.79 | FDPS (0.38) | — | |
| SCHEMBL1224912 | 0.74 | FDPS (0.33) | — | |
| SCHEMBL4086239 | 0.73 | — | — | |
| SCHEMBL14498520 | 0.73 | — | — | |
| SCHEMBL5510379 | 0.73 | FDPS (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258346-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240287061-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| US-11897878-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11786524-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| WO-2023186065-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023171736-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | 帝人ファーマ株式会社 | 2023-09-14 | — | — | WO | disclosed |
| WO-2023151642-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| US-20220213091-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-07 | — | — | US | disclosed |
| WO-2022059684-A1 | VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN | 帝人ファーマ株式会社 | 2022-03-24 | — | — | WO | disclosed |
| US-11203591-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| WO-2014134341-A1 | PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| US-7829741-B2 | Process for producing α, α-difluoroamine | NATIONAL UNIVERSITY CORPORATION (JP) | 2010-11-09 | — | — | US | disclosed |
| US-20090177012-A1 | PROCESS FOR PRODUCING ALPHA, ALPHA-DIFLUOROAMINE | NATIONAL UNIVERSITY CORPORATION, HOKKAIDO UNIVERSITY (JP) | 2009-07-09 | — | — | US | disclosed |
| CN-101012174-A | Halogenating agents | MITSUI CHEMICALS INC (JP) | 2007-08-08 | — | — | CN | disclosed |
| EP-1813596-A1 | PROCESS FOR PRODUCING ALPHA, ALPHA- DIFLUOROAMINE | National University Corporation Hokkaido University (JP) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007067362-A1 | IN SITU FLUORIDE ION-GENERATING COMPOSITIONS AND USES THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070129273-A1 | In situ fluoride ion-generating compositions and uses thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2007-06-07 | — | — | US | disclosed |
| CN-1202086-C | Halogenating agents | MITSUI CHEMICAL CO LTD (JP) | 2005-05-18 | — | — | CN | disclosed |
| CN-1483727-A | Halogenating agents | ������ѧ��ʽ���� | 2004-03-24 | — | — | CN | disclosed |
| CN-1218803-A | Halogenating agents | MITSUI CHEMICAL CO LTD (JP) | 1999-06-09 | — | — | CN | disclosed |